Table 1.

Anti-IL1 agents.

Biologic agent target cytokine(s)	Molecular characteristics	Doses (route of administration)	Recorded indications
Anakinra (Kineret) IL-1α and IL-1β	Recombinant human IL-1 receptor antagonist	100 mg/day (sc)	Rheumatoid arthritis
Rilonacept (Regeneron) IL-1α and IL-1β	Fusion protein of the extracellular domains of IL-1R1 and IL-1RAP, coupled to the Fc region of human IgG	Induction dose: 320 mg maintenance: 160 mg/week (sc)	Cryopyrin-associated periodic syndromes (CAPSs)
Canakinumab (Ilaris) IL-1β	Fully human monoclonal anti-IL1β antibody	150 mg every 8 weeks (sc)	Cryopirin-associated periodic syndromes (CAPSs)
Gevokizumab (Xoma 052) IL-1β	Recombinant humanized anti-IL1β antibody		Not labeled potential therapeutic use: Behçet's uveitis, types 1 and 2 diabetes, and rheumatoid arthritis (phase II trials)

sc: subcutaneous.